💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
User | Tweets |
---|---|
@newsfilterio | 3 |
@fintel_io | 2 |
@FlashAlert_me | 2 |
@AlertTrade | 2 |
@Biotech2050 | 2 |
![]() |
@SweepCastApp SweepCast observed: $XLRN with Unusual Options Activity Alerted on $140 CALL Expiring: 06-18-2021 worth 237K? |? Se… https://t.co/NvQg0UFFWo April 19th 2021, 6:04pm |
![]() |
@SweepCastApp SweepCast observed: $XLRN with Unusual Options Activity Alerted on $140 CALL Expiring: 06-18-2021 worth 237K? |? Se… https://t.co/5l3XiBMaWi April 18th 2021, 6:04pm |
![]() |
@MarketChmln $XLRN option volume was 15X normal on Friday with 2,255 contracts. Call volume was 55% and put volume was 45%. https://t.co/Sh2bIZBdee April 17th 2021, 5:04pm |
![]() |
@WALLSTREETODDS_ $XLRN Out of the 986 other times XLRN was down 1.9% during a trading day, 56% of the time it traded higher by the… https://t.co/rRH44OmVzd April 10th 2021, 1:04am |
![]() |
@deus_trader Optimus v4 2021-04-08 13:35 ET. Bought/Opened: $XLRN at $128.71. Acceleron Pharma, Inc (CORP). Win Chance: 71%. Av… https://t.co/Umh8osO0se April 8th 2021, 5:04pm |
![]() |
@AlertTrade RT @AlertTrade: REVERSALtoDOWN: $XLRN Acceleron Pharma, Inc https://t.co/vavn4UHszX ? ? TradeIdeas via ? https://t.co/VS8RO1bzXJ April 8th 2021, 4:04pm |
![]() |
@AlertTrade REVERSALtoDOWN: $XLRN Acceleron Pharma, Inc https://t.co/vavn4UHszX ? ? TradeIdeas via ? https://t.co/VS8RO1bzXJ April 8th 2021, 3:04pm |
![]() |
@bearcapital1 $XLRN I give this company no respect but prob the most consistent bio I follow in regards to execution. When I look… https://t.co/rfMCtz6bJ2 April 8th 2021, 12:04pm |
![]() |
@MarcJacksonLA $XLRN Acceleron Updates Phase 2 Sotatercept In Treating PAH Set For ATS 2021 https://t.co/pqh3LMfL49 April 7th 2021, 1:04pm |
![]() |
@YuZhu4 RT @Quantumup1: Credit Suisse $XLRN blue sky valuation of $250 is based on (1) a 90% probability of success for luspatercept in myelofibro… April 6th 2021, 6:04pm |
![]() |
@maxm_profit RT @SeekingAlpha: $XLRN - Acceleron: Neutral On Stock Price Gains. https://t.co/rb9i7XfSVw #markets #business #stockmarket April 6th 2021, 6:04pm |
![]() |
@insidersanalyt1 on 2021-04-05 $XLRN insiders' SOLD 21864 securities equal to 0.0361% of outstanding shares. #finance #trading… https://t.co/h2BUGLxN5s April 6th 2021, 6:04pm |
![]() |
@Biotech2050 RT @semodough: JP $XLRN believe data continue to underscore the differentiated clinical potential of sotatercept for PAH, offering added mo… April 6th 2021, 4:04pm |
![]() |
@semodough JP $XLRN believe data continue to underscore the differentiated clinical potential of sotatercept for PAH, offering… https://t.co/dQ0NChK4WX April 6th 2021, 4:04pm |
![]() |
@InsiderAlerts4U $XLRN: New Insider Filing on ACCELERON PHARMA INC's Director KAREN L. SMITH: https://t.co/MJasGOc7SM April 6th 2021, 8:04am |
![]() |
@newsfilterio $1,299,751.64 of shares sold by Smith Karen L. (Director), reported in a new form 4 filed with the SEC $XLRN https://t.co/b2KTbQIlth April 6th 2021, 5:04am |
![]() |
@newsfilterio $1,166,243.44 of shares sold by Zakrzewski Joseph S (Director), reported in a new form 4 filed with the SEC $XLRN https://t.co/07kcaOLqNh April 6th 2021, 5:04am |
![]() |
@newsfilterio Acceleron: Neutral On Stock Price Gains $XLRN https://t.co/rOFJ0gCnvc April 6th 2021, 3:04am |
![]() |
@Biotech2050 CS - $XLRN Updates from Sotatercept PULSAR and SPECTRA ATS Abstracts (Outperform PT raised to $151) #ATS21… https://t.co/WsA3suODLc April 6th 2021, 3:04am |
![]() |
@StckPro $XLRN NEW ARTICLE : Acceleron: Neutral On Stock Price Gains https://t.co/g2l3A8w87G Get all the latest $XLRN relate… https://t.co/ZHolChK45X April 6th 2021, 1:04am |
![]() |
@SeekingAlpha $XLRN - Acceleron: Neutral On Stock Price Gains. https://t.co/rb9i7XfSVw #markets #business #stockmarket April 6th 2021, 1:04am |
![]() |
@FlashAlert_me $XLRN [15s. delayed] filed SEC form 4: Director Zakrzewski Joseph S: Disposed 10,000 of Common Stock at average pr… https://t.co/cWwQ68R8p7 April 6th 2021, 12:04am |
![]() |
@fintel_io Insider Joseph S Zakrzewski reports selling 10,000 shares of $XLRN for a total cost of $1,407,343.44 https://t.co/Tq3qGBW5Z8 April 6th 2021, 12:04am |
![]() |
@formwhisperscom #FWSells $XLRN Smith Karen L., Director of ACCELERON PHARMA INC sold 11,864 shares on 2021-04-05. https://t.co/CXJ6yLgXfc April 6th 2021, 12:04am |
![]() |
@FlashAlert_me $XLRN [15s. delayed] filed SEC form 4: Director Smith Karen L.: Disposed 11,864 of Common Stock at average price $… https://t.co/vZuk1nAIOm April 6th 2021, 12:04am |
![]() |
@fintel_io Insider Smith Karen L. reports selling 11,864 shares of $XLRN for a total cost of $1,663,156.14 https://t.co/b8rIFxMb7Z April 6th 2021, 12:04am |
![]() |
@Quantumup1 Credit Suisse $XLRN blue sky valuation of $250 is based on (1) a 90% probability of success for luspatercept in my… https://t.co/49GbwXWPg4 April 5th 2021, 10:04pm |
![]() |
@MarcJacksonLA $XLRN HC Wainwright Maintains Buy Rating On Acceleron Pharma, $168 PT https://t.co/Y7I3w8oVeE April 5th 2021, 8:04pm |
![]() |
@MarcJacksonLA $XLRN Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hy… https://t.co/VxDV57YLrz April 5th 2021, 2:04pm |
![]() |
@Briefingcom $XLRN: Acceleron Pharma announced that updates from the PULSAR and SPECTRA Phase 2 clinical trials of sotatercept i… https://t.co/mD3zKs6ZRP April 5th 2021, 1:04pm |
![]() |
@Biotech2050 $XLRN abstracts https://t.co/e9tzjSnQsr April 5th 2021, 12:04pm |
![]() |
@PCCSMChiefs RT @AcceleronPharma: $XLRN announces updates from the PULSAR and SPECTRA Ph. 2 clinical trials of an investigational agent in #PAH that wil… April 5th 2021, 12:04pm |
![]() |
@EdgarInsider FORM 8-K [Press/News Current Report] recently SEC filed. $XLRN ACCELERON PHARMA INC https://t.co/xnO3NVckQz April 5th 2021, 11:04am |
![]() |
@fintel_io $XLRN / Acceleron Pharma files form 8-K - Financial Statements and Exhibits - 8-K https://t.co/VfqOU0xVtG April 5th 2021, 11:04am |
![]() |
@AcceleronPharma $XLRN announces updates from the PULSAR and SPECTRA Ph. 2 clinical trials of an investigational agent in #PAH that… https://t.co/nf5SJSC0Aa April 5th 2021, 11:04am |
![]() |
@BIOTECH888 RT @MSollender: $XLRN PULSAR and SPECTRA abstracts: https://t.co/FxFSe3h4ef https://t.co/lw1heObADp April 5th 2021, 11:04am |
![]() |
@MSollender $XLRN PULSAR and SPECTRA abstracts: https://t.co/FxFSe3h4ef https://t.co/lw1heObADp April 5th 2021, 11:04am |
![]() |
@stock_titan $XLRN Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hy… https://t.co/vM3bNAJk6v April 5th 2021, 11:04am |
![]() |
@insiderbuyings $XLRN new insider selling: 10000 shares. https://t.co/Ca3gOE5sTn April 3rd 2021, 7:04am |
![]() |
@formwhisperscom #FWSells $XLRN Smith Karen L., Director of ACCELERON PHARMA INC sold 8,925 shares on 2021-04-01. https://t.co/CXJ6yLgXfc April 3rd 2021, 3:04am |
![]() |
@fintel_io Insider Joseph S Zakrzewski reports selling 10,000 shares of $XLRN for a total cost of $1,346,382.36 https://t.co/Tq3qGBW5Z8 April 2nd 2021, 10:04pm |
![]() |
@newsfilterio $1,105,282.36 of shares sold by Zakrzewski Joseph S (Director), reported in a new form 4 filed with the SEC $XLRN https://t.co/GVSFelKV5m April 2nd 2021, 10:04pm |
![]() |
@fintel_io Insider Smith Karen L. reports selling 8,925 shares of $XLRN for a total cost of $1,218,002.72 https://t.co/b8rIFxMb7Z April 2nd 2021, 10:04pm |
![]() |
@newsfilterio $854,598.22 of shares sold by Smith Karen L. (Director), reported in a new form 4 filed with the SEC $XLRN https://t.co/YI7dZ5gW34 April 2nd 2021, 10:04pm |
![]() |
@MarcJacksonLA $XLRN New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with… https://t.co/8Q3IRKOKHC April 1st 2021, 2:04pm |
![]() |
@Briefingcom $XLRN: Acceleron Pharma announced the NEJM has published PULSAR Phase 2 trial results https://t.co/rzHbBvYwia April 1st 2021, 1:04pm |
![]() |
@StckPro $XLRN NEW ARTICLE : New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in… https://t.co/dOYBKvSOZB April 1st 2021, 11:04am |
![]() |
@sbwcws Acceleron says NEJM publishes results of Pulsar Phase 2 trial of sotatercept $XLRN April 1st 2021, 11:04am |
![]() |
@FlashAlert_me $XLRN [15s. delayed]: Issued Press Release on April 01, 07:00:00: New England Journal of Medicine Publishes Results… https://t.co/NBLqbCwsI2 April 1st 2021, 11:04am |
![]() |
@stock_titan $XLRN New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with… https://t.co/ErE9EXCGZm April 1st 2021, 11:04am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.